MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule ...
Pharmaceutical Technology on MSN
Congruence secures $39.5M to advance small molecule correctors pipeline
The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.
The financing was co-led by new investor Dimension and existing investor OrbiMed. Additional investors included Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capita ...
Montreal, Canada-based Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein ...
Congruence pulls in $50M series A to build a team of 'drug hunters' to go after rare disease targets
A new biotech called Congruence Therapeutics snagged $50 million to build a new team of "drug hunters" focused on protein misfolding to go after rare diseases. Congruence Therapeutics just completed a ...
- Programs in Parkinson's Disease and Alpha-1 antitrypsin deficiency progressing toward the clinic - MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics, a clinical-stage, computationally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results